1. Home
  2. TAOP vs SNGX Comparison

TAOP vs SNGX Comparison

Compare TAOP & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TAOP

Taoping Inc.

N/A

Current Price

$1.30

Market Cap

13.2M

Sector

Technology

ML Signal

N/A

Logo Soligenix Inc.

SNGX

Soligenix Inc.

N/A

Current Price

$1.18

Market Cap

12.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TAOP
SNGX
Founded
1993
1987
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
12.0M
IPO Year
2012
2006

Fundamental Metrics

Financial Performance
Metric
TAOP
SNGX
Price
$1.30
$1.18
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
6.8K
109.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$119,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$1.02
52 Week High
$8.78
$6.23

Technical Indicators

Market Signals
Indicator
TAOP
SNGX
Relative Strength Index (RSI) 41.61 52.34
Support Level $1.21 $1.19
Resistance Level $1.59 $1.22
Average True Range (ATR) 0.09 0.06
MACD 0.00 0.02
Stochastic Oscillator 19.44 86.67

Price Performance

Historical Comparison
TAOP
SNGX

About TAOP Taoping Inc.

Taoping Inc is a provider of cloud-app technologies for smart city IoT platforms, digital advertising delivery, and other internet-based information distribution systems in China. Its operating segment includes Cloud-based Technology (CBT), Blockchain Technology (BT), and Traditional Information Technology (TIT). It generates maximum revenue from the CBT segment. CBT segment includes cloud-based products and services offered to customers in the private sector including new media, healthcare, education, and residential community management.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: